Key Highlights

  • Revenue was USD 1.25 million against an estimate of USD 1.96 million.
  • Net loss per share was USD 3.76 against an estimate of a USD 2.00 loss.
  • Gross profit was USD 1.02 million, compared with USD 0.57 million.
  • Cash and cash equivalents were USD 4.75 million at September 30, 2026.

Scienture Holdings (NASDAQ:SCNX), formerly TRxADE HEALTH, reported Revenue of USD 1.25 million for the third quarter of 2026, compared with USD 0.59 million in the third quarter of 2025, against an estimate of USD 1.96 million. The net loss was USD 6.01 million, compared with USD 3.61 million, and the basic and diluted net loss per common share was USD 3.76, compared with USD 4.76, against an estimate of a USD 2.00 loss.

Gross Profit and Operating Expenses

Cost of sales was USD 0.23 million, compared with USD 0.02 million, and Gross Profit was USD 1.02 million, compared with USD 0.57 million. Wage and salary expense was USD 0.42 million, compared with USD 0.25 million, professional fees were USD 1.83 million, compared with USD 1.32 million, and accounting and legal expense was USD 0.17 million, compared with USD 1.02 million. General and administrative expense was USD 2.93 million, compared with USD 2.17 million, and Research and Development expense was USD 1.39 million, compared with USD 0.17 million.

Total operating expenses were USD 6.74 million, compared with USD 4.94 million, and the operating loss was USD 5.72 million, compared with USD 4.36 million. Interest expense was USD 0.38 million, compared with USD 1.80 million, and interest income was USD 0.14 million.

Nine-Month Results

For the nine months ended September 30, 2026, revenue was USD 1.65 million, compared with USD 0.60 million. The operating loss was USD 11.93 million, compared with USD 13.09 million, and the net loss was USD 12.23 million, compared with USD 13.39 million. The net loss per common share was USD 7.70, compared with USD 23.46.

Balance Sheet and Liquidity

Cash and cash equivalents were USD 4.75 million at September 30, 2026, compared with USD 6.66 million at December 31, 2025, and restricted cash was USD 3.03 million. Accounts receivable, net, were USD 2.22 million, compared with USD 0.73 million, and inventory was USD 1.00 million, compared with USD 0.21 million. Intangible assets, net, were USD 69.61 million, compared with USD 70.97 million, and total Assets were USD 87.18 million, compared with USD 84.18 million.

Total liabilities were USD 28.44 million, compared with USD 14.06 million, and the non-current note payable, net of Debt discount, was USD 9.20 million. The accumulated Deficit was USD 92.79 million. The filing states that the conditions initially indicated substantial doubt about the company's ability to continue as a going concern, and that management believes its plans alleviate that doubt for at least one year after the issuance of the financial statements.

Scienture Holdings Q3 2026 Earnings: Key Takeaways

Scienture Holdings reported third quarter 2026 revenue of USD 1.25 million and a net loss of USD 6.01 million. Cash and cash equivalents were USD 4.75 million at September 30, 2026.